PMV Pharmaceuticals
PMVP
74 hedge funds and large institutions have $58.2M invested in PMV Pharmaceuticals in 2024 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 23 increasing their positions, 31 reducing their positions, and 23 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more call options, than puts
Call options by funds: $20K | Put options by funds: $20K
2.97% less ownership
Funds ownership: 78.72% → 75.75% (-3%)
11% less capital invested
Capital invested by funds: $65.6M → $58.2M (-$7.44M)
20% less funds holding
Funds holding: 93 → 74 (-19)
26% less repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 31
83% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 23
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACH
ArrowMark Colorado Holdings
Denver,
Colorado
|
+$1.3M |
| 2 |
PHS
PFM Health Sciences
San Francisco,
California
|
+$1.14M |
| 3 |
SCM
Sio Capital Management
New York
|
+$782K |
| 4 |
BCM
BML Capital Management
Zionsville,
Indiana
|
+$586K |
| 5 |
Two Sigma Advisers
New York
|
+$398K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$1.02M |
| 2 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$770K |
| 3 |
Barclays
London,
United Kingdom
|
-$672K |
| 4 |
Millennium Management
New York
|
-$610K |
| 5 |
GTC
Ghost Tree Capital
New York
|
-$608K |
PMVP Hedge Fund Activity: Q3 2024 in Review
74 of the 6,965 institutional investors tracked by Wall St. Rank reported a position in PMV Pharmaceuticals (PMVP) for Q3 2024, worth a combined $58.2M — down 11% from $65.6M a quarter earlier.
Sellers outnumbered buyers: 23 funds closed out of PMVP and 4 opened new positions — a net loss of 19 holders — while 31 trimmed existing stakes and 23 added.
The largest buyer was ArrowMark Colorado Holdings, adding an estimated $1.3M. The largest seller was Citadel Advisors, cutting an estimated $1.02M.
- 74 institutional investors held PMV Pharmaceuticals (PMVP) as of Q3 2024, down from 93 in Q2 2024.
- Funds reported $58.2M of PMV Pharmaceuticals stock for Q3 2024, down 11% quarter-over-quarter.
- 4 funds opened new PMV Pharmaceuticals positions in Q3 2024 and 23 closed out, a net change of -19 holders.
- The largest PMV Pharmaceuticals buyer in Q3 2024 was ArrowMark Colorado Holdings, an estimated $1.3M added.
- The largest PMV Pharmaceuticals seller in Q3 2024 was Citadel Advisors, an estimated $1.02M sold.
Based on aggregated 13F filings for Q3 2024.